Search

Your search keyword '"de Souza, Carmino A."' showing total 133 results

Search Constraints

Start Over You searched for: Author "de Souza, Carmino A." Remove constraint Author: "de Souza, Carmino A." Database Unpaywall Remove constraint Database: Unpaywall
133 results on '"de Souza, Carmino A."'

Search Results

1. Kinetics of BCR::ABL1 transcript levels and molecular relapse after tyrosine kinase inhibitors discontinuation in chronic myeloid leukemia patients: preliminary results from the DES-CML study

3. Treatment outcomes in classic Hodgkin lymphoma: 5‐year update from the Brazilian Hodgkin Lymphoma Registry

4. CML-425 Evaluation of Antibody Responses among Five Different SARS-Cov-2 Vaccines in Chronic Myeloid Leukemia (CML) Patients – A Real-World Study

5. POSTER: CML-425 Evaluation of Antibody Responses among Five Different SARS-Cov-2 Vaccines in Chronic Myeloid Leukemia (CML) Patients – A Real-World Study

6. P1199: CLINICAL UPSHOTS OF PIONEER PROJECT TO COLLECT DATA OF T-CELL NHL PATIENTS AMONG FIVE REGIONS OF BRAZIL. T-CELL BRAZIL PROJECT.

7. PB1977: EVALUATION OF ANTIBODY RESPONSES AMONG FIVE DIFFERENT SARS-COV-2 VACCINES IN CHRONIC MYELOID LEUKEMIA PATIENTS – A REAL-WORLD STUDY

8. Treatment patterns and outcomes for Hodgkin Lymphoma patients aged 60 and older: a report from the Brazilian Prospective Hodgkin Lymphoma Registry

9. T084: Treatment patterns and outcomes for Hodgkin’s Lymphoma (HL) patients (pts) aged 60 and older: a report from the Brazilian Prospective Hodgkin’s lymphoma Registry

10. P018: Treatment outcomes in classical Hodgkin lymphoma (HL): 5-year update report from the Brazilian Prospective Registry

12. AN UPDATED OF PIONEER PROJECT TO COLLECT DATA OF T-CELL NHL PATIENTS AMONG FIVE REGIONS OF BRAZIL. T-CELL BRAZIL PROJECT

13. Characteristics and clinical outcomes of patients with ALK‐positive anaplastic large cell lymphoma: Report from the prospective international T‐cell lymphoma project

14. Metabolic Volume Measurements in Multiple Myeloma

19. COVID-19 in chronic myeloid leukemia patients in Latin America

21. How’s going on the T-Cell Brazil project

22. ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project

23. Efficacy and safety of pioglitazone in a phase 1/2 imatinib discontinuation trial ( EDI‐PIO ) in chronic myeloid leukemia with deep molecular response

24. 99mTc-sestamibi SPECT/CT and 18F-FDG-PET/CT have similar performance but different imaging patterns in newly diagnosed multiple myeloma

25. Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project

26. Impact of SNPs/Haplotypes of IL10 and IFNG on the Development of Diffuse Large B-Cell Lymphoma

27. Proposal for a Quantitative 18F-FDG PET/CT Metabolic Parameter to Assess the Intensity of Bone Involvement in Multiple Myeloma

30. Cardiovascular Risk and Cardiovascular Events in Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors

31. B3a2 Transcript Is an Independent Factor for the Achievement of a Deep Molecular Response in Chronic Phase - Chronic Myeloid Leukemia Patients Treated with Imatinib in First-Line

32. Efficacy and Safety of Generic Imatinib Compared to Glivec in Chronic Phase - Chronic Myeloid Leukemia - a Multicenter, Observational Study

34. Frequency of EBV associated classical Hodgkin lymphoma decreases over a 54-year period in a Brazilian population

37. Lower socioeconomic status is independently associated with shorter survival in Hodgkin Lymphoma patients—An analysis from the Brazilian Hodgkin Lymphoma Registry

38. Treatment outcomes for Hodgkin lymphoma: First report from the Brazilian Prospective Registry

39. Phase II trial of dasatinib (DAS) in pediatric patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP).

40. VEGF, VEGFR2 and GSTM1 polymorphisms in Outcome of Multiple Myeloma Patients in the Thalidomide Era

41. Influence of BCR-ABL Transcript Type on Outcome in Patients with Chronic-Phase Chronic Myeloid Leukemia Treated with Imatinib 400 Mg

42. Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial

43. Synergistic effect of KIR ligands missing and cytomegalovirus reactivation in improving outcomes of haematopoietic stem cell transplantation from HLA-matched sibling donor for treatment of myeloid malignancies

46. Age-adjusted international prognostic index is a predictor of survival in gastric diffuse B-cell non-Hodgkin lymphoma patients

49. Pre-Transplant Beta2-Microglobulin Is an Independent Biomarker of Acute Graft-Versus-Host-Disease after Allogeneic Hematopoietic Cell Transplant in a Single Institutional Study

Catalog

Books, media, physical & digital resources